<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484248</url>
  </required_header>
  <id_info>
    <org_study_id>14110467</org_study_id>
    <nct_id>NCT02484248</nct_id>
  </id_info>
  <brief_title>Trial of Ketotifen in Children and Adolescents</brief_title>
  <acronym>Ketotifen</acronym>
  <official_title>Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, placebo -controlled, cross-over trial of ketotifen in children
      ages 8 through 17 inclusive that have a diagnosis of Functional Dyspepsia and have had
      continued pain despite acid reduction therapy in combination with montelukast. This study is
      147 days for subjects responsive to the ketotifen and 63 days for those who are not. The
      study includes scheduled visits including a physical, blood draws, and questionaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to assess the symptomatic response to ketotifen as compared to placebo in
      children and adolescents with functional dyspepsia in association with duodenal eosinophilia
      who have previously had worsening, no clinical change, or only a partial response to
      acid-reduction therapy in combination with montelukast.

      Secondary aims include: 1) assessing the impact of ketotifen as compared to placebo on
      quality of life; 2) assessing the impact of ketotifen as compared to placebo on state and
      trait anxiety; 3) assessing whether baseline trait anxiety is predictive of clinical response
      to ketotifen; 4) assessing whether functional dyspepsia subtype is predictive of response to
      ketotifen, 5) assessing the sustainability of response to ketotifen in initial responders,
      and 6) assessing the pharmacokinetics of ketotifen in this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Physical (the study physician will check all systems and ask questions about pain and symptoms) Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period.</time_frame>
    <description>Physician directed physical (the study physician will check all systems and ask questions about pain and symptoms). This is a comprehensive system check to ensure safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure,Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>A Trained professional to complete blood pressure. To ensure value is within normal range and ensure safety of patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Functioning Test (a test ran from a blood sample to check a patients liver functioning)Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>Blood Sample collected and tested by a Certified Laboratory. Liver Functioning Test (a test ran from a blood sample to check a patients liver functioning). This will be completed and verified to be within normal ranges by the study physician to ensure patient safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>State-Trait Inventory for Cognitive and Somatic Anxiety - Child Version, Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>Anxiety Score testing via questionaire. This will be used to look at how anxiety corelates with pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pediatric Quality of Life Inventory, Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>Quality of life survey for pediatrics. This will be completed to ensure maintenance of quality of life throughout study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate, Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>A Trained professional to complete heart rate. To ensure value is within normal range and ensure safety of patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate, Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>A Trained professional to complete respiratory rate. To ensure value is within normal range and ensure safety of patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Sampling(Area under the plasma concentration versus time curve (AUC)) , Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>Pharmacokinetics sampling to be completed for safety. This will be completed to evaluate the entire process of the drug breakdown by the body and ensure long term-effects and safety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Sampling(Peak Plasma Concentration (Cmax)), Change is being assessed.</measure>
    <time_frame>day 0, day 28, day 63, and day 147. Change is being assessed from each time period</time_frame>
    <description>Pharmacokinetics sampling to be completed for safety.This will be completed to evaluate the entire process of the drug breakdown by the body and ensure long term-effects and safety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>cross-over of Ketotifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm patients will begin the active Ketotifen treatment first and cross over to the placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cross-over of Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm patients will begin the placebo treatment first and cross over to the active Ketotifen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen</intervention_name>
    <description>Ketotifen is a anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.</description>
    <arm_group_label>cross-over of Ketotifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>cross-over of Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. between the ages of 8 and 17 years, inclusive

          2. abdominal pain of at least 8 weeks duration and fulfilling symptom-based criteria for
             functional dyspepsia(5);

          3. previous endoscopy with biopsies demonstrating &gt;20 eosinophils/high powered field on
             duodenal mucosal biopsies;

          4. previous treatment with acid-reduction therapy and montelukast with a level 3 (as
             defined below)or lesser response;

          5. evidence of written parental permission (consent) and subject assent;

          6. Negative pregnancy screening for females of child bearing potential.

        Exclusion Criteria:

          1. previous treatment with ketotifen;

          2. treatment with corticosteroids or oral cromolyn sodium in the four weeks prior to
             enrollment;

          3. any prior history of diabetes mellitus, cancer, chronic cardiac disease, respiratory
             disease, or renal disease requiring routine medical care;

          4. Pregnant/planning to become pregnant;

          5. Post-menarche females unwilling to use highly-efficacious contraception to prevent
             pregnancy;

          6. Epilepsy or history of seizures;

          7. Liver disease or elevation of liver enzymes;

          8. Use of oral hypoglycemic medications, antipsychotics, benzodiazepines, tricyclic
             antidepressants, barbiturates, or opioids;

          9. Allergy to ketotifen or other products in capsule

         10. Refusal of Urine pregnancy test in post-menarchal females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Craig A Friesen, M.D.</last_name>
    <phone>816-983-6975</phone>
    <email>cfriesen@cmh.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trevor J Cole, BS</last_name>
    <phone>816-983-6025</phone>
    <email>tjcole@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig A Friesen, MD</last_name>
      <phone>816-983-6985</phone>
      <email>cfriesen@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Trevor J Cole, BS</last_name>
      <phone>816-983-6025</phone>
      <email>tjcole@cmh.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>The FO, Buist MR, Lei A, Bennink RJ, Hofland J, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol. 2009 Sep;104(9):2257-66. doi: 10.1038/ajg.2009.268. Epub 2009 Jun 2.</citation>
    <PMID>19491822</PMID>
  </reference>
  <reference>
    <citation>McFadyen ML, Miller R, Ludden TM. Ketotifen pharmacokinetics in children with atopic perennial asthma. Eur J Clin Pharmacol. 1997;52(5):383-6.</citation>
    <PMID>9272408</PMID>
  </reference>
  <reference>
    <citation>http://www.drugs.com/mmx/ketotifen-fumarate.html</citation>
  </reference>
  <reference>
    <citation>Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010 Sep;59(9):1213-21. doi: 10.1136/gut.2010.213108. Epub 2010 Jul 21.</citation>
    <PMID>20650926</PMID>
  </reference>
  <reference>
    <citation>Suzuki J, Kawasaki Y, Nozawa R, Isome M, Suzuki S, Takahashi A, Suzuki H. Oral disodium cromoglycate and ketotifen for a patient with eosinophilic gastroenteritis, food allergy and protein-losing enteropathy. Asian Pac J Allergy Immunol. 2003 Sep;21(3):193-7.</citation>
    <PMID>15032404</PMID>
  </reference>
  <reference>
    <citation>Vithayasai N, Jennuvat S, Lertsatit A. Eosinophilic gastrointestinal disease: analysis of sixteen cases from ten years experience in Thailand. J Med Assoc Thai. 2011 Aug;94 Suppl 3:S41-8.</citation>
    <PMID>22043753</PMID>
  </reference>
  <reference>
    <citation>Tien FM, Wu JF, Jeng YM, Hsu HY, Ni YH, Chang MH, Lin DT, Chen HL. Clinical features and treatment responses of children with eosinophilic gastroenteritis. Pediatr Neonatol. 2011 Oct;52(5):272-8. doi: 10.1016/j.pedneo.2011.06.006. Epub 2011 Jul 27.</citation>
    <PMID>22036223</PMID>
  </reference>
  <reference>
    <citation>www.octoberhealth.com/images/Ketotifen_1mg_Product_Information.pdf</citation>
  </reference>
  <reference>
    <citation>Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology. 2006 Apr;130(5):1466-79. Review. Erratum in: Gastroenterology. 2006 Jul;131(1):336.</citation>
    <PMID>16678560</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Hunter HL, Friesen CA. Conceptualization and treatment of chronic abdominal pain in pediatric gastroenterology practice. J Pediatr Gastroenterol Nutr. 2010 Jan;50(1):32-7. doi: 10.1097/MPG.0b013e3181ae3610.</citation>
    <PMID>19915496</PMID>
  </reference>
  <reference>
    <citation>Chogle A, Dhroove G, Sztainberg M, Di Lorenzo C, Saps M. How reliable are the Rome III criteria for the assessment of functional gastrointestinal disorders in children? Am J Gastroenterol. 2010 Dec;105(12):2697-701. doi: 10.1038/ajg.2010.350. Epub 2010 Aug 31.</citation>
    <PMID>20808296</PMID>
  </reference>
  <reference>
    <citation>Walker LS, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, Caplan A, Rasquin-Weber A. Recurrent abdominal pain: symptom subtypes based on the Rome II Criteria for pediatric functional gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 2004 Feb;38(2):187-91.</citation>
    <PMID>14734882</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Friesen CA, Danda CE, Andre L, Welchert E, Lavenbarg T, Cocjin JT, Hyman PE. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. J Pediatr Gastroenterol Nutr. 2005 Sep;41(3):291-5.</citation>
    <PMID>16131983</PMID>
  </reference>
  <reference>
    <citation>Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006 Apr;130(5):1527-37.</citation>
    <PMID>16678566</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.</citation>
    <PMID>20479684</PMID>
  </reference>
  <reference>
    <citation>Rippel SW, Acra S, Correa H, Vaezi M, Di Lorenzo C, Walker LS. Pediatric patients with dyspepsia have chronic symptoms, anxiety, and lower quality of life as adolescents and adults. Gastroenterology. 2012 Apr;142(4):754-61. doi: 10.1053/j.gastro.2011.12.043. Epub 2012 Jan 5.</citation>
    <PMID>22226783</PMID>
  </reference>
  <reference>
    <citation>Aro P, Talley NJ, Agréus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, Ronkainen J. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011 Jun;33(11):1215-24. doi: 10.1111/j.1365-2036.2011.04640.x. Epub 2011 Mar 28.</citation>
    <PMID>21443537</PMID>
  </reference>
  <reference>
    <citation>Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993 Sep;38(9):1590-5.</citation>
    <PMID>8359068</PMID>
  </reference>
  <reference>
    <citation>O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000 Oct;12(5):449-57.</citation>
    <PMID>11012945</PMID>
  </reference>
  <reference>
    <citation>Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004 Mar;126(3):693-702.</citation>
    <PMID>14988823</PMID>
  </reference>
  <reference>
    <citation>Hall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9.</citation>
    <PMID>15017654</PMID>
  </reference>
  <reference>
    <citation>Choi MG, Park SJ, Lee SY, Cho YK, Park JM, Han HW, Oh JW, Lee IS, Chung IS. Association of psychological factors with activation of mucosal immune system in functional dyspepsia. Neurogastroenterol Motil 2004; 16:668</citation>
  </reference>
  <reference>
    <citation>Walker MM, Talley NJ, Prabhakar M, Pennaneac'h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR, Agreus L. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009 Apr 1;29(7):765-73. doi: 10.1111/j.1365-2036.2009.03937.x. Epub 2009 Jan 17.</citation>
    <PMID>19183150</PMID>
  </reference>
  <reference>
    <citation>Hou XH, Zhu LR, Li QX, Chen JDZ. Alterations in mast cells and 5-HT positive cells in gastric mucosa in functional dyspepsia patients with hypersensitivity. Neurogastroenterol Motil 2001; 13:398-399</citation>
  </reference>
  <reference>
    <citation>Friesen CA, Lin Z, Singh M, Singh V, Schurman JV, Burchell N, Cocjin JT, McCallum RW. Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008 Oct;53(10):2634-40. doi: 10.1007/s10620-008-0207-0. Epub 2008 Mar 5.</citation>
    <PMID>18320315</PMID>
  </reference>
  <reference>
    <citation>Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol. 1996 Feb;9(2):110-4.</citation>
    <PMID>8657715</PMID>
  </reference>
  <reference>
    <citation>Kalach N, Huvenne H, Gosset P, Papadopoulos S, Dehecq E, Decoster A, Creusy C, Dupont C. Eosinophil counts in upper digestive mucosa of Western European children: variations with age, organs, symptoms, Helicobacter pylori status, and pathological findings. J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):175-82. doi: 10.1097/MPG.0b013e3181e2ae00.</citation>
    <PMID>20890222</PMID>
  </reference>
  <reference>
    <citation>Erjefält JS, Greiff L, Andersson M, Adelroth E, Jeffery PK, Persson CG. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax. 2001 May;56(5):341-4.</citation>
    <PMID>11312400</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Andre L, Garola R, Hodge C, Roberts C. Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):329-33.</citation>
    <PMID>12352522</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agréus L. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83. Epub 2007 Aug 7.</citation>
    <PMID>17686660</PMID>
  </reference>
  <reference>
    <citation>Thakkar K, Chen L, Tatevian N, Shulman RJ, McDuffie A, Tsou M, Gilger MA, El-Serag HB. Diagnostic yield of oesophagogastroduodenoscopy in children with abdominal pain. Aliment Pharmacol Ther. 2009 Sep 15;30(6):662-9. doi: 10.1111/j.1365-2036.2009.04084.x. Epub 2009 Jul 2.</citation>
    <PMID>19573168</PMID>
  </reference>
  <reference>
    <citation>Kokkonen J, Ruuska T, Karttunen TJ, Niinimäki A. Mucosal pathology of the foregut associated with food allergy and recurrent abdominal pains in children. Acta Paediatr. 2001 Jan;90(1):16-21.</citation>
    <PMID>11227327</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009 May 11;9:32. doi: 10.1186/1471-230X-9-32.</citation>
    <PMID>19432972</PMID>
  </reference>
  <reference>
    <citation>Buhner S, Schemann M. Mast cell-nerve axis with a focus on the human gut. Biochim Biophys Acta. 2012 Jan;1822(1):85-92. doi: 10.1016/j.bbadis.2011.06.004. Epub 2011 Jun 17. Review.</citation>
    <PMID>21704703</PMID>
  </reference>
  <reference>
    <citation>Woodruff SA, Masterson JC, Fillon S, Robinson ZD, Furuta GT. Role of eosinophils in inflammatory bowel and gastrointestinal diseases. J Pediatr Gastroenterol Nutr. 2011 Jun;52(6):650-61. doi: 10.1097/MPG.0b013e3182128512. Review.</citation>
    <PMID>21593640</PMID>
  </reference>
  <reference>
    <citation>Ochi H, De Jesus NH, Hsieh FH, Austen KF, Boyce JA. IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10509-13.</citation>
    <PMID>10973484</PMID>
  </reference>
  <reference>
    <citation>Santos J, Alonso C, Guilarte M, Vicario M, Malagelada JR. Targeting mast cells in the treatment of functional gastrointestinal disorders. Curr Opin Pharmacol. 2006 Dec;6(6):541-6. Epub 2006 Sep 7. Review.</citation>
    <PMID>16956793</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo C, Colletti RB, Lehmann HP, Boyle JT, Gerson WT, Hyams JS, Squires RH Jr, Walker LS, Kanda PT; AAP Subcommittee; NASPGHAN Committee on Chronic Abdominal Pain. Chronic Abdominal Pain In Children: a Technical Report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2005 Mar;40(3):249-61. Review.</citation>
    <PMID>15735476</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Danda CE, Friesen CA, Hyman PE, Simon SD, Cocjin JT. Variations in psychological profile among children with recurrent abdominal pain. J Clin Psychol Med Settings. 2008 Sep;15(3):241-51. doi: 10.1007/s10880-008-9120-0. Epub 2008 Jul 25.</citation>
    <PMID>19104969</PMID>
  </reference>
  <reference>
    <citation>Liu L, Li Q, Sapolsky R, Liao M, Mehta K, Bhargava A, Pasricha PJ. Transient gastric irritation in the neonatal rats leads to changes in hypothalamic CRF expression, depression- and anxiety-like behavior as adults. PLoS One. 2011 May 12;6(5):e19498. doi: 10.1371/journal.pone.0019498.</citation>
    <PMID>21589865</PMID>
  </reference>
  <reference>
    <citation>Chrousos GP. Stress, chronic inflammation, and emotional and physical well-being: concurrent effects and chronic sequelae. J Allergy Clin Immunol. 2000 Nov;106(5 Suppl):S275-91. Review.</citation>
    <PMID>11080744</PMID>
  </reference>
  <reference>
    <citation>Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut. 1998 Jun;42(6):845-9.</citation>
    <PMID>9691924</PMID>
  </reference>
  <reference>
    <citation>Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006 Feb;130(2):304-11.</citation>
    <PMID>16472586</PMID>
  </reference>
  <reference>
    <citation>Posserud I, Agerforz P, Ekman R, Björnsson ES, Abrahamsson H, Simrén M. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut. 2004 Aug;53(8):1102-8.</citation>
    <PMID>15247175</PMID>
  </reference>
  <reference>
    <citation>Böhmelt AH, Nater UM, Franke S, Hellhammer DH, Ehlert U. Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med. 2005 Mar-Apr;67(2):288-94.</citation>
    <PMID>15784796</PMID>
  </reference>
  <reference>
    <citation>Dickhaus B, Mayer EA, Firooz N, Stains J, Conde F, Olivas TI, Fass R, Chang L, Mayer M, Naliboff BD. Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. Am J Gastroenterol. 2003 Jan;98(1):135-43.</citation>
    <PMID>12526949</PMID>
  </reference>
  <reference>
    <citation>Wallon C, Söderholm JD. Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon. Ann N Y Acad Sci. 2009 May;1165:206-10. doi: 10.1111/j.1749-6632.2009.04030.x.</citation>
    <PMID>19538308</PMID>
  </reference>
  <reference>
    <citation>Zheng PY, Feng BS, Oluwole C, Struiksma S, Chen X, Li P, Tang SG, Yang PC. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut. 2009 Nov;58(11):1473-9. doi: 10.1136/gut.2009.181701. Epub 2009 Aug 2.</citation>
    <PMID>19651632</PMID>
  </reference>
  <reference>
    <citation>He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004 Feb 1;10(3):309-18. Review.</citation>
    <PMID>14760748</PMID>
  </reference>
  <reference>
    <citation>Santos J, Saperas E, Nogueiras C, Mourelle M, Antolín M, Cadahia A, Malagelada JR. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998 Apr;114(4):640-8.</citation>
    <PMID>9516384</PMID>
  </reference>
  <reference>
    <citation>Coruzzi G, Adami M, Pozzoli C. Role of histamine H4 receptors in the gastrointestinal tract. Front Biosci (Schol Ed). 2012 Jan 1;4:226-39. Review.</citation>
    <PMID>22202056</PMID>
  </reference>
  <reference>
    <citation>La JH, Yang IS. Peripheral CRF mediates visceral hypersensitivity by activating mucosal mast cells in IBS rats. Neurogastroenterol Motil 2005; 17(Suppl 2):39</citation>
  </reference>
  <reference>
    <citation>Wood JD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology. 2004 Aug;127(2):635-57. Review.</citation>
    <PMID>15300595</PMID>
  </reference>
  <reference>
    <citation>Larauche M. Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity. Neurogastroenterol Motil. 2012 Mar;24(3):201-5. doi: 10.1111/j.1365-2982.2011.01867.x.</citation>
    <PMID>22316289</PMID>
  </reference>
  <reference>
    <citation>Walker MM, Warwick A, Ung C, Talley NJ. The role of eosinophils and mast cells in intestinal functional disease. Curr Gastroenterol Rep. 2011 Aug;13(4):323-30. doi: 10.1007/s11894-011-0197-5. Review.</citation>
    <PMID>21552990</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Schurman JV, Qadeer A, Andre L, Welchert E, Cocjin J. Relationship between mucosal eosinophils and anxiety in pediatric dyspepsia. Gastroenterology 2005; 129:A-158</citation>
  </reference>
  <reference>
    <citation>Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, Kitamori S, Nakagawa S, Shimizu Y, Takeda H, Asaka M. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:27-31.</citation>
    <PMID>15943843</PMID>
  </reference>
  <reference>
    <citation>Amini M, Ghamar Chehreh ME, Khedmat H, Valizadegan G, Babaei M, Darvishi A, Taheri S. Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial. J Egypt Public Health Assoc. 2012 Apr;87(1-2):29-33. doi: 10.1097/01.EPX.0000410948.64665.66.</citation>
    <PMID>22415333</PMID>
  </reference>
  <reference>
    <citation>Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:32-6.</citation>
    <PMID>15943844</PMID>
  </reference>
  <reference>
    <citation>Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005 Jul;100(7):1477-88.</citation>
    <PMID>15984968</PMID>
  </reference>
  <reference>
    <citation>Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, Karlberg J, Wong BC. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007 Feb;5(2):178-85; quiz 140. Epub 2006 Dec 14.</citation>
    <PMID>17174612</PMID>
  </reference>
  <reference>
    <citation>Talley NJ, Meineche-Schmidt V, Paré P, Duckworth M, Räisänen P, Pap A, Kordecki H, Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther. 1998 Nov;12(11):1055-65.</citation>
    <PMID>9845395</PMID>
  </reference>
  <reference>
    <citation>Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med. 2004 Jun 1;116(11):740-8.</citation>
    <PMID>15144910</PMID>
  </reference>
  <reference>
    <citation>van Rensburg C, Berghöfer P, Enns R, Dattani ID, Maritz JF, Gonzalez Carro P, Fischer R, Schwan T. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin. 2008 Jul;24(7):2009-18. doi: 10.1185/03007990802184545 . Epub 2008 Jun 4.</citation>
    <PMID>18534050</PMID>
  </reference>
  <reference>
    <citation>See MC, Birnbaum AH, Schechter CB, Goldenberg MM, Benkov KJ. Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. Dig Dis Sci. 2001 May;46(5):985-92.</citation>
    <PMID>11341669</PMID>
  </reference>
  <reference>
    <citation>Dehghani SM, Imanieh MH, Oboodi R, Haghighat M. The comparative study of the effectiveness of cimetidine, ranitidine, famotidine, and omeprazole in treatment of children with dyspepsia. ISRN Pediatr. 2011;2011:219287. doi: 10.5402/2011/219287. Epub 2011 Apr 5. Erratum in: ISRN Pediatr. 2013;2013:206546.</citation>
    <PMID>22389770</PMID>
  </reference>
  <reference>
    <citation>Wood JD. Neuropathophysiology of irritable bowel syndrome. J Clin Gastroenterol. 2002 Jul;35(1 Suppl):S11-22. Review.</citation>
    <PMID>12184133</PMID>
  </reference>
  <reference>
    <citation>Milenov K, Todorov S, Vassileva M, Zamfirova R, Shahbazian A. Interactions between histaminergic and cholinergic pathways of gastric motility regulation. Methods Find Exp Clin Pharmacol. 1996 Jan-Feb;18(1):33-9.</citation>
    <PMID>8721254</PMID>
  </reference>
  <reference>
    <citation>Izzo AA, Costa M, Mascolo N, Capasso F. The role of histamine H1, H2 and H3 receptors on enteric ascending synaptic transmission in the guinea pig ileum. J Pharmacol Exp Ther. 1998 Dec;287(3):952-7.</citation>
    <PMID>9864278</PMID>
  </reference>
  <reference>
    <citation>Jiang W, Kreis ME, Eastwood C, Kirkup AJ, Humphrey PP, Grundy D. 5-HT(3) and histamine H(1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats. Gastroenterology. 2000 Nov;119(5):1267-75.</citation>
    <PMID>11054384</PMID>
  </reference>
  <reference>
    <citation>Moharana AK, Bhattacharya SK, Mediratta PK, Sharma KK. Possible role of histamine receptors in the central regulation of immune responses. Indian J Physiol Pharmacol. 2000 Apr;44(2):153-60.</citation>
    <PMID>10846628</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Sandridge L, Andre L, Roberts CC, Abdel-Rahman SM. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006 Mar;45(2):143-7.</citation>
    <PMID>16528434</PMID>
  </reference>
  <reference>
    <citation>Matter SE, Bhatia PS, Miner PB Jr. Evaluation of antral mast cells in nonulcer dyspepsia. Dig Dis Sci. 1990 Nov;35(11):1358-63.</citation>
    <PMID>2226097</PMID>
  </reference>
  <reference>
    <citation>Shahriar M, Mizuguchi H, Maeyama K, Kitamura Y, Orimoto N, Horio S, Umehara H, Hattori M, Takeda N, Fukui H. Suplatast tosilate inhibits histamine signaling by direct and indirect down-regulation of histamine H1 receptor gene expression through suppression of histidine decarboxylase and IL-4 gene transcriptions. J Immunol. 2009 Aug 1;183(3):2133-41. doi: 10.4049/jimmunol.0901058. Epub 2009 Jul 13.</citation>
    <PMID>19596986</PMID>
  </reference>
  <reference>
    <citation>Shirai T, Hashimoto D, Suzuki K, Osawa S, Aonahata M, Chida K, Nakamura H. Successful treatment of eosinophilic gastroenteritis with suplatast tosilate. J Allergy Clin Immunol. 2001 May;107(5):924-5.</citation>
    <PMID>11344364</PMID>
  </reference>
  <reference>
    <citation>Lunardi C, Bambara LM, Biasi D, Cortina P, Peroli P, Nicolis F, Favari F, Pacor ML. Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance. Clin Exp Allergy. 1991 Sep;21(5):569-72.</citation>
    <PMID>1742648</PMID>
  </reference>
  <reference>
    <citation>Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G. Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol. 1992 Jan;87(1):55-7.</citation>
    <PMID>1728124</PMID>
  </reference>
  <reference>
    <citation>Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995 Jun;30(6):535-41.</citation>
    <PMID>7569760</PMID>
  </reference>
  <reference>
    <citation>Ree MJ, French D, MacLeod C, Locke V. Distinguishing cognitive and somatic dimensions of state and trait anxiety: Development and validation of the State-Trait Inventory for Cognitive and Somatic Anxiety (STICSA). Behavioral and Cognitive Psychotherapy 2008; 36: 313-332</citation>
  </reference>
  <reference>
    <citation>http://www.pedsql.org/about_pedsql.html 82</citation>
  </reference>
  <reference>
    <citation>Chen X, Zhong D, Liu D, Wang Y, Han Y, Gu J. Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom. 2003;17(22):2459-63.</citation>
    <PMID>14608613</PMID>
  </reference>
  <reference>
    <citation>Grahnén A, Lönnebo A, Beck O, Eckernäs SA, Dahlström B, Lindström B. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos. 1992 May;13(4):255-62.</citation>
    <PMID>1600111</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2015</study_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Craig A. Friesen, MD</investigator_full_name>
    <investigator_title>Division Cheif Gastroenterologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

